Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Nicolo Rampi, Belen Hervas Sanz, Carolina Esther Arevalo Leon, Angelo Castellani, Patricia Lopez Pereira, Elena Bechtold Javier, Ana C de Oliveira, Sara Pacella, Carmen Aguilera, Anna Valer, Eva Gonzalez Barca, Francesca Gaia Rossi, Carolina Martinez-Ramos, Ana Maria Sureda Balari, Montserrat Cortes-Romera, Eva Domingo Domenech

Blood (2024) 144 (Supplement 1): 6417.

https://doi.org/10.1182/blood-2024-210108

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Blood (2024) 144 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2024-208828

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Eugenio Fardella, Giada Zanirato, Martina Magni, Nicole Caldarelli, Annalisa Chiappella, Anna Dodero, Silva Ljevar, Lorella Orsucci, Alessandro Re, Sara Usai, Vittorio Stefoni, Claudia Castellino, Francesca Gaia Rossi, Antonio Pinto, Cristiana Carniti, Paolo Corradini

Blood (2023) 142 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2023-189215

Published: 2023

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Simoultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience

Anna Ines Gregorini, MD, Francesca Gaia Rossi, MD, Sara Lodi Rizzini, MD, Valeria Ferla, MD, Giorgia Saporiti, MD, Loredana Pettine, MD, Mariarita Sciumè, MD, Fabio Serpenti, MD, Veronica Mattiello, Maria Chiara Barbanti, MD, Giorgio Maggioni, Luca Baldini, MD PhD, Roberto Scarani, MD, Massimo Pizzuto, MD, Francesco Onida, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142631

Published: 2020

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Michele Merli, MD, Stefano Luminari, MD, Lucia Farina, Federica Cocito, MD, Irene Defrancesco, MD, Guido Gini, MD, Annalisa Arcari, MD, Greta Scapinello, MD, Massimo Gentile, MD, Maria Goldaniga, MD, Giacomo Loseto, MD, Emanuele Cencini, MD, Antonino Greco, MD, Andrea Ferrario, MD, Benedetta Bianchi, MD, Francesca Gaia Rossi, MD, Silvia Bolis, MD, Francesco Passamonti, MD, Luca Arcaini, MD

Blood (2018) 132 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2018-99-113536

Published: 2018

Journal Articles

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Blood (2018) 132 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2018-99-114023

Published: 2018

Journal Articles

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

Alessandra Pompa, MD, Anna Ines Gregorini, MD, Francesca Guidotti, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Riccardo Marcolin, Luca Baldini, MD Prof, Agostino Cortelezzi, MD

Blood (2016) 128 (22): 5734.

https://doi.org/10.1182/blood.V128.22.5734.5734

Published: 2016

Journal Articles

Four Cases of Lenalidomide-Associated Immune Thrombocytopenia

Alessandra Pompa, MD, Francesca Guidotti, MD, Anna Ines Gregorini, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Luca Baldini, MD Prof, Agostino Cortelezzi, MD

Blood (2016) 128 (22): 4927.

https://doi.org/10.1182/blood.V128.22.4927.4927

Published: 2016

Journal Articles

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Blood (2013) 122 (23): 3759–3766.

https://doi.org/10.1182/blood-2013-06-507319

Published: 2013

Includes: Supplemental data

Journal Articles

A Retrospective Analysis of Mantle Cell Lymphoma Patients Series Treated Upfront by Sequential High Dose Immunochemotherapy Supported by In Vivo Purged Stem Celle Double Autologous Transplantation: A Monocentric Experience

Andrea Ferrario, MD, Giorgia Saporiti, MD, Nicola Orofino, MD, Francesco Onida, MD, Daniele Vincenti, MD, Claudia Basilico, MD, Francesca Gaia Rossi, MD, Barbara Olivero, MD, Maria Cecilia Goldaniga, MD, Elena Tagliaferri, MD, Claudio Annaloro, MD, Luca Baldini, Prof

Blood (2011) 118 (21): 4949.

https://doi.org/10.1182/blood.V118.21.4949.4949

Published: 2011

Journal Articles

Genome-Wide Analysis of Primary Plasma-Cell Leukemia Identifies Recurrent Imbalances Associated with Transcriptional Profile Alterations

Blood (2011) 118 (21): 2878.

https://doi.org/10.1182/blood.V118.21.2878.2878

Published: 2011

Journal Articles

Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients

Andrea Ferrario, MD, Alessio Aghemo, MD, Maria Cecilia Goldaniga, MD, Michele Merli, MD, Daniele Vincenti, MD, Francesca Gaia Rossi, MD, Elisabetta De Gasperi, MD, Barbara Olivero, MD, Lilla Cro, PhD, Sara Rattotti, MD, Luca Arcaini, MD, Francesco Onida, MD, Luca Baldini, Prof

Blood (2010) 116 (21): 2876.

https://doi.org/10.1182/blood.V116.21.2876.2876

Published: 2010

Journal Articles

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Antonio Salar, MD, PhD, Corinne Haioun, MD, Francesca Gaia Rossi, MD, Ulrich Duehrsen, MD, Ruth Pettengell, Hans Erik Johnsen, MD, Ulrich Jaeger, MD, Gregor Verhoef, Matthias Schwenkglenks, PhD, Fernando Principe, MD, Pamela Bacon, PhD, Kate Bendall, P.J. Lugtenburg, MD, PhD

Blood (2009) 114 (22): 107.

https://doi.org/10.1182/blood.V114.22.107.107

Published: 2009

NARROW

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Simoultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

Four Cases of Lenalidomide-Associated Immune Thrombocytopenia

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

A Retrospective Analysis of Mantle Cell Lymphoma Patients Series Treated Upfront by Sequential High Dose Immunochemotherapy Supported by In Vivo Purged Stem Celle Double Autologous Transplantation: A Monocentric Experience

Genome-Wide Analysis of Primary Plasma-Cell Leukemia Identifies Recurrent Imbalances Associated with Transcriptional Profile Alterations

Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only